Moneycontrol PRO

Buy Sanofi India; target of Rs 8300: Sharekhan

Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 8300 in its research report dated July 26, 2022.

July 28, 2022 / 08:42 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sharekhan's research report on Sanofi India


Emphasis on leveraging the digital platform and divestment of the slow-moving business is expected to drive OPM expansion, leading to a high single-digit PAT CAGR over the next two years. High-growth visibility from chronics, strong and debt-free balance sheet, sturdy dividends, and healthy cash position are the key positives. Sanofi has declared a special interim dividend of Rs 193 per share for CY2022.



Outlook


We retain our Buy recommendation on the stock of Sanofi with a revised PT of Rs 8300 Sanofi has reported a weak result for Q2CY22, though the numbers are not comparable on a y-o-y basis due to divesture of business.

Close

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Sanofi India - 270722 - khan

Broker Research
first published: Jul 28, 2022 08:42 pm
Sections
ISO 27001 - BSI Assurance Mark